- Home
- SDA vs APLT Comparison
SDA vs APLT Comparison
Compare SDA & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SDA | APLT |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.5M | 18.0M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | SDA | APLT |
|---|---|---|
| Price | $2.09 | $0.11 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $4.75 | $1.25 |
| AVG Volume (30 Days) | 76.4K | ★ 8.4M |
| Earning Date | 12-18-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $467,272,000.00 | $1,000,000.00 |
| Revenue This Year | $10.86 | $124.18 |
| Revenue Next Year | $13.07 | $66.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.69 | N/A |
| 52 Week Low | $1.54 | $0.10 |
| 52 Week High | $10.61 | $1.50 |
Technical Indicators
Market Signals| Indicator | SDA | APLT |
|---|---|---|
| Relative Strength Index (RSI) | 57.02 | 25.94 |
| Support Level | $1.98 | $0.10 |
| Resistance Level | $2.09 | $0.13 |
| Average True Range (ATR) | 0.10 | 0.02 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 92.89 | 7.28 |
Price Performance
Historical ComparisonAbout SDA SunCar Technology Group Inc.
SunCar Technology Group Inc operates digital automotive aftersales market service platform and vehicle insurance technology platform. It develops and operates online platforms that connect drivers in China with a range of aftermarket automotive services and insurance coverage options from a nationwide network of service providers. These comprehensive digital systems are built on SunCar's multi-tenant, cloud-based platform.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.